Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP. (Q53253769)

12 May 2018

title

Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP. (English)

1 reference

12 May 2018

diffuse large B-cell lymphoma

1 reference

1 reference

9

Cheolwon Suh

1 reference

12 May 2018

author name string

Changhoon Yoo

1

1 reference

12 May 2018

Dae Ho Lee

2

1 reference

12 May 2018

Jeong Eun Kim

3

1 reference

12 May 2018

Jungmin Jo

4

1 reference

12 May 2018

Dok Hyun Yoon

5

1 reference

12 May 2018

Byeong Seok Sohn

6

1 reference

12 May 2018

Sang-We Kim

7

1 reference

12 May 2018

Jung-Shin Lee

8

1 reference

12 May 2018

publication date

22 December 2010

1 reference

12 May 2018

published in

Annals of Hematology

1 reference

12 May 2018

volume

90

1 reference

12 May 2018

issue

7

1 reference

12 May 2018

page(s)

797-802

1 reference

12 May 2018

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1135-6

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1135-6

Prognostic biomarkers in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1135-6

Imaging in staging of malignant lymphoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1135-6

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1135-6

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1135-6

[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1135-6

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1135-6

FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1135-6

Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1135-6

Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1135-6

High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1135-6

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1135-6

Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1135-6

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1135-6

Prognostic value of early 18 fluorodeoxyglucose positron emission tomography and gallium-67 scintigraphy in aggressive lymphoma: a prospective comparative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1135-6

FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1135-6

10.1007/S00277-010-1135-6

21 January 2018

Identifiers

DOI

1 reference

12 May 2018

1 reference

12 May 2018